Haitian Program for Research and Training in HIV/AIDS

海地艾滋病毒/艾滋病研究和培训方案

• 批准号: 7292144
• 负责人: JEAN WILLIAM PAPE
• 金额: $ 10.71万
• 依托单位: GHESKIO CENTER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-01 至 2007-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7292144
• 关键词: AIDS therapy; CD4 molecule; Caribbean islands; HIV infections; Mycobacterium tuberculosis; antiAIDS agent; clinical research; clinical trials; cooperative study; data management; disease /therapy duration; efavirenz; enzyme linked immunosorbent assay; ethics; flow cytometry; health science research support; human therapy evaluation; lamivudine; microorganism immunology; patient oriented research; sign /symptom; training; tuberculosis; zidovudine

DESCRIPTION (provided by applicant): The goal of this application is to prepare the GHESKIO Centers in Port-au-Prince, Haiti for a multi-project CIPRA in five years. This goal will be achieved through the conduct of a randomized clinical trial of early versus delayed antiretroviral therapy for people with pre-AIDS symptomatic HIV disease and through research training and capacity building. The GHESKIO Centers, directed by Jean Pape, is a Haitian non-governmental research and training organization working in close partnership with the Haitian Government on HIV/AIDS. Over the next five years, GHESKIO will become a regional HIV/AIDS center providing training and conducting research in collaboration with partners in Haiti and the Caribbean. The specific aims are: Aim 1: To determine the optimal time to start antiretroviral therapy (ART). We propose to conduct a randomized clinical trial to determine the outcome of early versus delayed antiretroviral therapy (ART) in HIV infected adults with pre-AIDS symptomatic HIV disease (WHO Sate II or III symptoms, such as pulmonary TB, chronic diarrhea, or oral thrush) and a CD4 count between 200 and 350 cells/mm3. The primary hypothesis is: Early initiation of ART in HIV infected adults with pre-AIDS symptoms and a CD4 count between 200 and 350 cells/mm3 will improve survival at 36 months when compared to delaying ART until subjects develop clinical AIDS (WHO stage IV) or CD4 count <200 cells/mm3. Aim 2: To build on the existing capacity of the GHESKIO Center in Port au Prince Haiti and to prepare for a multi-project CIPRA within five years. Capacity will be increased in: 1) Administration, including development of an advisory council, increasing ethics capacity, strengthening grants management, and strengthening training. 2) Clinical investigation; 3) Data management and analysis; 4) Laboratory capacity including HIV virology and immunology. In each of these capacity building areas, we have identified promising young Haitians who will participate in the CIPRA project and who will also receive advanced training and mentorship by senior investigators from the US. These Haitians will be leaders in a multi-project CIPRA in five years.

描述（由申请人提供）：本申请的目的是为海地港口港口的Gheskio中心准备五年内的多项目cipra。 通过对患有预艾滋病症状的艾滋病毒疾病的患者以及研究培训和能力建设的早期和延迟抗逆转录病毒疗法的随机临床试验，将实现此目标。 由让·帕普（Jean Pape）执导的Gheskio中心是海地非政府研究和培训组织，与海地政府与艾滋病毒/艾滋病（HIV/AIDS）密切合作。 在接下来的五年中，Gheskio将成为一个区域艾滋病毒/艾滋病中心，与海地和加勒比海的合作伙伴合作提供培训和研究。 具体目的是：目标1：确定开始抗逆转录病毒疗法（ART）的最佳时间。 我们建议进行一项随机临床试验，以确定患有艾滋病毒感染的抗逆转录病毒疗法（ART）的结果，患有预辅助治疗的成年人有症状的HIV疾病（他们有II或III个症状，例如肺结核，慢性腹泻，或口服鹅口疮或口服鹅口疮）和200和350 Cells/350 Cells/mmMMM 3。 主要假设是：与延迟ART延迟ART，直到受试者开发临床AIDS（WHO阶段IV）或CD4计数<200细胞/mm3，在36个月中，患有预辅助症状的艾滋病毒感染的成年人的ART早期开始，CD4计数在36个月时将提高生存率。 AIM 2：建立在海地港口港的Gheskio中心的现有能力，并在五年内为多项目的CIPRA做准备。 容量将增加： 1）行政管理，包括成长咨询委员会，提高道德能力，加强赠款管理和加强培训。 2）临床研究； 3）数据管理和分析； 4）实验室能力，包括HIV病毒学和免疫学。 在这些能力建设区域中的每个区域中，我们都确定了有希望的年轻海地人，他们将参加CIPRA项目，并还将获得美国高级调查员的高级培训和指导。 这些海地人将在五年内成为多个项目的领导者。